Tilmicosin and tylosin have anti-inflammatory properties via modulation of COX-2 and iNOS gene expression and production of cytokines in LPS-induced macrophages and monocytes

International Journal of Antimicrobial Agents

Volumn 27, Issue 5, 2006, Pages 442-449

  Cao, Xing Yuan ^a   Dong, Mei ^b   Shen, Jian Zhong ^a   Wu, Bei Bei ^a   Wu, Cong Ming ^a   Du, Xiang Dang ^a   Wang, Zhuo ^a   Qi, Yi Tao ^a   Li, Bing yu ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cyclooxygenase 2; Cytokines; Inducible nitric oxide synthase; Macrophage; PBMC; Tilmicosin

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CYCLOOXYGENASE 2; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROLIDE; NITRIC OXIDE; PROSTAGLANDIN E2; TILMICOSIN; TUMOR NECROSIS FACTOR ALPHA; TYLOSIN;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; ESCHERICHIA COLI; GENE EXPRESSION; IN VITRO STUDY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 33646155335     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.12.010     Document Type: Article

References (44)

1. Baumann H., and Gauldie J. The acute phase response. Immunol Today 15 (1994) 74-89
2. Kröncke K.D., Fehsel K., Suschek C., and Kolb-Bachofen V. Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival. Int Immunopharmacol 1 (2001) 1407-1420
3. Kim S.S., Oh O.J., Min H.Y., et al. Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells. Life Sci 73 (2003) 337-348
4. Mongan L.C., Jones T., and Patrick G. Cytokine and free radical responses of alveolar macrophages in vitro to asbestos fibres. Cytokine 12 (2000) 1243-1247
5. Stadnyk A.W., Gillan T.L., and Anderson R. Respiratory syncytial virus triggers synthesis of IL-6 in BALB/c mouse alveolar macrophages in the absence of virus replication. Cell Immunol 176 (1997) 122-126
6. Inui Y., Azuma Y., and Ohura K. Differential alteration of functions of rat peritoneal macrophages responsive to endogenous opioid peptide endomorphin-1. Int Immunopharmacol 2 (2002) 1133-1142
7. Liew F.Y. The role of innate cytokines in inflammatory response. Immunol Lett 85 (2003) 131-134
8. Fodor L., Reeve-Johnson L., Hodge A., and Varga J. Efficacy evaluations of the use of oral tilmicosin in pneumonic calves. Vet J 159 (2000) 194-200
9. Picavet T., Muylle E., Devriese L.A., and Geryl J. Efficacy of tilmicosin in treatment of pulmonary infections in calves. Vet Rec 129 (1991) 400-403
10. Naccari F., Giofre F., Pellegrino M., Calo M., Licata P., and Carli S. Effectiveness and kinetic behaviour of tilmicosin in the treatment of respiratory infections in sheep. Vet Rec 148 (2001) 773-776
11. Moore G.M., Mowrey D.H., Tonkinson L.V., Lechtenberg K.F., and Schneider J.H. Efficacy dose determination study of tilmicosin phosphate in feed for control of pneumonia caused by Actinobacillus pleuropneumoniae in swine. Am J Vet Res 57 (1996) 220-223
12. Naccari F., Martino D., Giofrè F., et al. Therapeutic efficacy of tilmicosin in ovine mammary infections. Small Rumin Res 47 (2003) 1-9
13. Scorneaux B., and Shryock T.R. Intracellular accumulation, subcellular distribution and efflux of tilmicosin in swine phagocytes. J Vet Pharmacol Ther 21 (1998) 257-268
14. Scorneaux B., and Shryock T.R. Intracellular accumulation, subcellular distribution, and efflux of tilmicosin in bovine mammary, blood, and lung cells. J Dairy Sci 82 (1999) 1202-1212
15. Jordan W.H., Byrd R.A., Cochrane R.L., et al. A review of the toxicology of the antibiotic MICOTIL 300. Vet Hum Toxicol 35 (1993) 151-158
16. Hartman E.G., and Geryl J. Comparison between the minimal inhibitory concentration of tilmicosin and oxytetracycline for bovine pneumonic Pasteurella haemolytica isolates. Vet Q 15 (1993) 184
17. Chin A.C., Morck D.W., Merrill J.K., et al. Anti-inflammatory benefits of tilmicosin in calves with Pasteurella haemolytica-infected lungs. Am J Vet Res 59 (1998) 765-771
18. Chin A.C., Lee W.D., Murrin K.A., et al. Tilmicosin induces apoptosis in bovine peripheral neutrophils in the presence or in the absence of Pasteurella haemolytica and promotes neutrophil phagocytosis by macrophages. Antimicrob Agents Chemother 44 (2000) 2465-2470
19. Lee W.D., Flynn A.N., LeBlanc J.M., et al. Tilmicosin-induced bovine neutrophil apoptosis is cell-specific and downregulates spontaneous LTB4 synthesis without increasing Fas expression. Vet Res 35 (2004) 213-224
20. Lakritz J., Tyler J.W., Marsh A.E., Romesburg-Cockrell M., Smith K., and Holle J.M. Tilmicosin reduces lipopolysaccharide-stimulated bovine alveolar macrophage prostaglandin E(2) production via a mechanism involving phospholipases. Vet Ther 3 (2002) 7-21
21. Kohri K., Tamaoki J., Kondo M., Aoshiba K., Tagaya E., and Nagai A. Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. Eur Respir J 15 (2000) 62-67
22. Ianaro A., Ialenti A., Maffia P., et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 292 (2000) 156-163
23. Khan A.A., Slifer T.R., Araujo F.G., and Remington J.S. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 11 (1999) 121-132
24. Morikawa K., Watabe H., Araake M., and Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 40 (1996) 1366-1370
25. Liu Y., Peterson D.A., Kimura H., and Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 69 (1997) 581-593
26. 15N] nitrate in biological fluids. Anal Biochem 126 (1982) 131-138
27. 1α. Methods Enzymol 86 (1982) 273-286
28. Wang H.Q., and Smart R.C. Overexpression of protein kinase C-alpha in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-alpha expression but not tumor promotion. J Cell Sci 112 (1999) 3497-3506
29. Bian K., Harari Y., Zhong M., et al. Down-regulation of inducible nitric-oxide synthase (NOS-2) during parasite-induced gut inflammation: a path to identify a selective NOS-2 inhibitor. Mol Pharmacol 59 (2001) 939-947
30. Kreiss C., Birder L.A., Kiss S., VanBibber M.M., and Bauer A.J. COX-2 dependent inflammation increases spinal Fos expression during rodent postoperative ileus. Gut 52 (2003) 527-534
31. Huang C.-J., Stevens B.R., Nielsen R.B., et al. Interleukin-10 inhibition of nitric oxide biosynthesis involves suppression of CAT-2 transcription. Nitric Oxide 6 (2002) 79-84
32. Niiro H., Otsuka T., Ogami E., et al. MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes. Biochem Biophys Res Commun 250 (1998) 200-205
33. Lang R., Rutschman R.L., Greaves D.R., and Murray P.J. Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. J Immunol 168 (2002) 3402-3411
34. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., and Mier J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83 (1994) 113-118
35. Muller J.M., Ziegler-Heitbrock H.W., and Baeuerle P.A. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 187 (1993) 233-256
36. Xie Q.W., Kashiwabara Y., and Nathan C. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem 269 (1994) 4705-4708
37. Yamamoto K., Arakawa T., Ueda N., and Yamamoto S. Transcriptional roles of nuclear factor κB and nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270 (1995) 31315-31320
38. Ichiyama T., Nishikawa M., Yoshitomi T., et al. Clarithromycin inhibits NF-κB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 45 (2001) 44-47
39. Vodovotz Y., Bogdan C., Paik J., Xie Q.W., and Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β. J Exp Med 178 (1993) 605-613
40. Ziv G., Shem-Tov M., Glickman A., Winkler M., and Saran A. Tilmicosin antibacterial activity and pharmacokinetics in cows. J Vet Pharmacol Ther 18 (1995) 340-345
41. Ramadan A. Pharmacokinetics of tilmicosin in serum and milk of goats. Res Vet Sci 62 (1997) 48-50
42. Patel K.B., Xuan D., Tessier P.R., Russomanno J.H., Quintiliani R., and Nightingale C.H. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 40 (1996) 2375-2379
43. Modric S., Webb A.I., and Derendorf H. Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. J Vet Pharmacol Ther 21 (1998) 444-452
44. Shen J., Li C., Jiang H., et al. Pharmacokinetics of tilmicosin after oral administration in swine. Am J Vet Res 66 (2005) 1071-1074